An international team led by researchers at The Hospital for Sick Children (SickKids), Princess Margaret Cancer Centre, Dalhousie University, the University of Exeter (UK) and the Medical University of Vienna (Austria) has uncovered a surprising way compartments within cells work together to defend themselves against oxidative stress, a finding that could shift how we understand age-associated conditions such as diabetes and neurodegenerative diseases.

Receiving six or more prescriptions of the drug gabapentin for low back pain is associated with significantly increased risks of developing dementia and mild cognitive impairment (MCI) - 29% and 85%, respectively - finds a large medical records study published online in the journal Regional Anesthesia & Pain Medicine.

What's more, these risks were more than twice as high in those normally considered too young to develop either condition - 18 - 64 year olds - the findings indicate.

A research team led by Prof. LIU Qingsong and Prof. LIU Jing from the Hefei Institutes of Physical Science, Chinese Academy of Sciences, has recently developed a new class of compounds that effectively inhibit both wild-type CDK9 and its drug-resistant mutant form, offering a promising strategy for treating hematological malignancies.

A new study by University of Bath scientists has highlighted two new potential families of drug molecules that could open the door to new treatments for tuberculosis.

Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, is the second largest infectious killer globally after COVID-19 and causes 1.3 million deaths annually.

A new study led by researchers at Lund University in Sweden, reveals that melanoma, the deadliest form of skin cancer, can in some cases be driven by mitochondrial processes, which can be effectively targeted using existing drugs. In preclinical laboratory experiments with melanoma cell cultures, researchers successfully eliminated cancer cells by using antibiotics and inhibitors of mitochondrial energy production, highlighting a potential therapeutic breakthrough.

A new study by investigators from Europe, including the Netherlands and the United Kingdom (UK), has shed light on significant ethical, administrative, regulatory, and logistical (EARL) hurdles in delivering multinational randomized clinical trials. The research was the first to comprehensively quantify these barriers for an international platform trial and emphasizes the need for urgent improvements, particularly in preparing for future public health crises.

Researchers working on an incurable blood cancer can now use a new lab model which could make testing potential new treatments and diagnostics easier and quicker, new research has found.

In a paper published in Nature Communications a team of researchers led from the University of Birmingham have studied blood cells from patients with a blood cancer called myelodysplastic syndrome disease (MDS).